Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
MEDI9253 + Durvalumab for Solid Cancers
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing a new drug, MEDI9253, in combination with durvalumab to see if it is safe and effective in treating adults with certain types of advanced solid tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.